We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+8.2%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$667M
AUM Growth
+$23.1M
Cap. Flow
+$3.29M
Cap. Flow %
0.49%
Top 10 Hldgs %
55.8%
Holding
54
New
10
Increased
20
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$24.5M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$21.8M
3
TWST icon
Twist Bioscience
TWST
+$14M
4
JANX icon
Janux Therapeutics
JANX
+$7.44M
5
AQST icon
Aquestive Therapeutics
AQST
+$6.99M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$13.4M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$12.6M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$11M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$10.9M
5
AXSM icon
Axsome Therapeutics
AXSM
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
51
Scholar Rock
SRRK
$7.04B
– –
-1,028,330
Closed -$8.57M
VERV
52
DELISTED
Verve Therapeutics
VERV
– –
-638,163
Closed -$3.11M
XERS icon
53
Xeris Biopharma Holdings
XERS
$1.55B
– –
-4,830,526
Closed -$10.9M
MORF
54
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-369,384
Closed -$12.6M
1 2
3

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q3 2024 Portfolio in Review

As of Q3 2024, MPM BioImpact held 54 positions worth $667M, up 3.6% from $644M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

MPM BioImpact's Q3 2024 filing shows 10 new, 20 increased, 7 reduced and 11 closed positions. Its largest new stake was Rocket Pharmaceuticals: 1,066,373 shares worth $19.7M. The largest sale was Alkermes, an estimated $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM BioImpact's largest Q3 2024 buy was Rocket Pharmaceuticals: 1,066,373 shares worth $19.7M.
  • MPM BioImpact added most to Avidity Biosciences in Q3 2024, an estimated $24.5M increase.
  • MPM BioImpact's biggest Q3 2024 reduction was 89bio, cutting an estimated $6.66M.
  • MPM BioImpact fully exited Alkermes in Q3 2024, selling an estimated $13.4M.
  • MPM BioImpact's ten largest holdings make up 56% of its $667M portfolio in Q3 2024.
  • MPM BioImpact opened 10 new positions and closed 11 in Q3 2024.
  • MPM BioImpact's portfolio value rose 3.6% quarter-over-quarter to $667M.

Based on MPM BioImpact's 13F filing for Q3 2024, filed 13 Nov 2024.